– CANADA, Mississauga – Nuvo Pharmaceuticals Inc. (TSX: MRV | OTC: MRVFF) dba Miravo Healthcare, today announced the appointment of Dale Weil to its Board of Directors, effective on May 16, 2022.
“On behalf of the Company and the Board of Directors, I would like to thank David Copeland, our outgoing director, for his years of service on the Board in the capacity of Lead Director and Chair of the Audit Committee.” said Board chair, Rob Harris.
Jesse Ledger, CEO, added, “We are pleased to welcome Dale as a member of our Board of Directors. Her experience in the healthcare industry and her engagements on various boards will provide invaluable insights as we continue to execute our strategy.”
About Dale MacCandlish Weil
Dale Weil is currently the Executive Director of the Teresa Dellar Palliative Care Residence and Montreal Institute for Palliative Care. She is also a Director for Theratechnologies and Tetra Bio-Pharma. From 1999 to 2018, Mrs. Weil was with McKesson Canada Corporation, holding leadership roles including SVP Integrated Healthcare and Pharmaceutical Solutions, SVP Integrated Healthcare Solutions, Strategy and Business Development, and Senior Advisor to the President.
Before joining McKesson Canada, Mrs. Weil spent 20 years at John Labatt Ltd., Ault Foods, and Parmalat Canada in progressive roles in marketing, strategy, sales, and general management.
Mrs. Weil holds a BSC in Marine Biology, an MBA from McGill University, and is a certified director from the ICD Directors Education Program.
About Miraval Healthcare
Miravo is a Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, neurology, and dermatology. The Company’s strategy is to in-license and acquires growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices environment respecting the U.S., Canada, and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration.
For more information: https://www.miravohealthcare.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.